Phase 2 ADHD Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Children and teenagers between 6 and 18 years old who have been diagnosed with ADHD by a neurologist, psychiatrist, or other specialist, using the DSM-V diagnostic guidelines
- People who are able and willing to attend all required visits as set out in the study plan
Who may not be able to join:
- People who have used standard ADHD medications in the month before the study starts, or who plan to use them during the study
- People who have used benzodiazepines (a type of sedative/anxiety medication) or older-generation antihistamines in the week before the study starts, or other medications the study doctor believes could interfere with the study
- People who have a neurological or psychiatric condition (other than ADHD)
- People who have or have had a cancer-related illness
- People who have a diagnosed syndrome or metabolic condition
- People with another significant medical diagnosis that the study doctor believes could interfere with the study (confirm with trial site, as some may be considered for inclusion later)
- Teenagers who are pregnant or breastfeeding
- Female teenagers who are sexually active and unwilling to use contraception during the study
- People whom the study doctor believes will not be able to follow the study rules in a way that could affect the results
- People who weigh less than 18 kg or more than 90 kg
- People whose BMI is below 18 or above 29.9
- People who are currently taking part in another clinical trial involving a medicine
- People who are currently taking part in any other study about ADHD treatment of any kind
- People who use alcohol or recreational drugs
- People who currently use or have previously used cannabis, including medical cannabis
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Matitiahu Berkovitch, MD, Shamir Medical Center, Zerifin, Israel
Phone: +972-89778465
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Improvement in hyperactivity sub-score of the Conners' Parent Questionnaire, as compared with baseline.; Improvement in inattentiveness sub-score of the Conners' Parent Questionnaire, as compared with baseline.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.